Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Banyan Readies For Pivotal Study Of Molecular Dx For Traumatic Brain Injury

This article was originally published in The Gray Sheet

Executive Summary

Banyan Biomarkers blood-based assay works by detecting the presence of two proteins that only cross the blood-brain barrier if there’s been a brain injury. An IDE was filed July 2 and the firm hopes for PMA approval in 2014.

You may also be interested in...



First Concussion Blood Test Leverages De Novo, Breakthrough Pathways

The Banyan Brain Trauma Indicator is the first blood test for detecting concussions in adults to reach the US market and the second device to emerge from US FDA's Breakthrough Devices Program. While test-maker Banyan Biomarkers originally flirted with the PMA pathway, FDA swayed it to the de novo process, which the firm ultimately leveraged to gain the market go-ahead.

Brain Injury Diagnostics Workshop Planned By FDA

The workshop will evaluate potential diagnostics, development strategies and datasets for traumatic brain injury. Multiple firms are working to bring different technologies for concussion detection to market.

Devices Rank Front And Center In Cleveland Clinic’s 'Top 10' Picks

The Cleveland Clinic has identified seven up-and-coming device technologies that are likely to have major clinical impact and see near-term commercial success, as part of its annual “Top 10 Medical Innovations” list.

Related Content

Related Companies

UsernamePublicRestriction

Register

LL1134885

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel